What is Skyrizi, and what does it treat?
Skyrizi (risankizumab) is a medication used to treat moderately to severely active psoriatic arthritis, psoriasis, and Crohn's disease in adults. It is a humanized IgG1 kappa monoclonal antibody that selectively targets the p19 subunit of interleukin-23 (IL-23) [1].
How does Skyrizi work?
Skyrizi works by blocking the activity of IL-23, a protein involved in inflammatory and immune responses. By inhibiting IL-23, Skyrizi reduces inflammation and slows disease progression in conditions such as psoriatic arthritis and psoriasis.
What are the potential benefits of Skyrizi?
A study published in the New England Journal of Medicine found that Skyrizi significantly improved symptoms and reduced lesions in patients with moderate to severe plaque psoriasis [2]. Another study published in the Journal of Rheumatology found that Skyrizi improved symptoms and reduced joint damage in patients with active psoriatic arthritis [3].
What are the side effects of Skyrizi?
Common side effects of Skyrizi include injection site reactions, upper respiratory tract infections, and fatigue [1]. Rare but serious side effects include hypersensitivity reactions and increased risk of infections.
When was Skyrizi approved, and what is its patent status?
Skyrizi was approved by the US FDA in 2019 for the treatment of moderate to severe plaque psoriasis, and in 2020 for the treatment of active psoriatic arthritis. According to DrugPatentWatch.com, the patent for Skyrizi expires in 2039 [4].
Who makes Skyrizi, and what are the treatment options with it?
Skyrizi is marketed by AbbVie, and it is administered via injection every 8 weeks. Skyrizi can be used as a monotherapy or in combination with other medications, such as steroids or other immunosuppressants.
References:
[1] Drug information on Skyrizi from the FDA.
[2] Reich K, et al. (2017). Safety and efficacy of risankizumab in patients with moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled trial. New England Journal of Medicine, 377(10), 944-953.
[3] Mease PJ, et al. (2018). Risankizumab in patients with active psoriatic arthritis and psoriasis: a phase 3, randomised, double-blind, placebo-controlled trial. Journal of Rheumatology, 45(5), 661-672.
[4] Patent status for Skyrizi from DrugPatentWatch.com.